Clinical trial
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in…
NCT00094809 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00094809 |
|---|---|
| Title | Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer |
| Official title | Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer, Colorectal Cancer, Rectal Cancer |
| Intervention type | Drug |
| Interventions | Placebo, Pegfilgrastim |
| Enrollment | 252 |
| Start date | Feb 1, 2003 |
| Primary completion | May 19, 2006 |
| Completion | Jan 23, 2008 |
| First posted | Oct 26, 2004 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: